Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial

Intermittent FOLFIRI plus PAN after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2024-11-22
DOI
https://doi.org/10.1200/jco.24.00979
Citations
8
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
2.26

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial

Vincenzo Montesarchio, Alfredo Colombo, Gerardo Rosati, Giuseppe Santabarbara et al.
8 citations
Journal of Clinical Oncology
Colorectal Cancer Treatments and Studies
2.26
article

Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial

Vincenzo Montesarchio, Alfredo Colombo, Gerardo Rosati, Giuseppe Santabarbara, Emiliano Tamburini, Antonella Petrillo, Alfredo Budillon, Alfonso De Stefano, Paolo Delrio, Silvana Leo, Francesco Mannavola, Carmela Romano, Lucrezia Silvestro, Alessandra Leone, Mariapia Laterza, Antonio Febbraro, Guglielmo Nasti, Claudio Lotesoriere, Antonino Cassata, Francesco Giuliani, Diana Giannarelli, Antonio Avallone, Francesco Izzo, Alberto F. Sobrero, Daniele Santini, Anna Giulia Nappi
article en
8 citations

Abstract

Intermittent FOLFIRI plus PAN after the induction phase was feasible, and the primary end point was met with reduced toxicity while allowing patients more time off treatment.

Journal of Clinical OncologyVol. 43(7)
Policlinico Umberto I (IT), Agostino Gemelli University Polyclinic (IT), Azienda Ospedaliera S.Giuseppe Moscati (IT), Ospedale Monaldi (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Ospedale Policlinico San Martino (IT), Ospedale Vito Fazzi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Gastroenterology Hospital "Saverio de Bellis" (IT), ASST Fatebenefratelli Sacco (IT)
Amgen
Good health and well-being
Openalex Percentile: Top 10%
Colorectal Cancer Treatments and Studies
2.26
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.